Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | ADH1B | P00325 | 2/20 | 0.34 |
| ▸ | ADH1C | P00326 | 2/20 | 0.34 |
| ▸ | ADH1A | P07327 | 2/20 | 0.34 |
| ▸ | ADH7 | P40394 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828392 | 0.98 | TSHR (0.41) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL828184 | 0.93 | TSHR (0.36) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL11905930 | 0.77 | TSHR (0.39) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL11905504 | 0.77 | TSHR (0.39) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL11905229 | 0.77 | TSHR (0.39) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL7907072 | 0.73 | TSHR (0.40) | TSHRTHRBLMNAALDH1A1 | |
| SCHEMBL10618203 | 0.71 | TSHR (0.35) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL6017704 | 0.71 | TSHR (0.41) | TSHRFAAHTHRBLMNAALDH1A1 | |
| SCHEMBL25404161 | 0.70 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL11024773 | 0.69 | TSHR (0.47) | TSHREPHX1THRBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1950216-B1 | PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND | MITSUI CHEMICALS INC (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-8211984-B2 | Ring-opening metathesis polymer, hydrogenated product thereof, method for preparing the same, and use thereof | MITSUI CHEMICALS, INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8143429-B2 | Process for producing organic transition metal complex compound, metathesis catalyst produced by using the same, ring-opening metathesis polymer obtainable with the metathesis catalyst, and process for producing the polymer | MITSUI CHEMICALS, INC. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090215974-A1 | RING-OPENING METATHESIS POLYMER, HYDROGENATED PRODUCT THEREOF, METHOD FOR PREPARING THE SAME, AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090124772-A1 | PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND, METATHESIS CATALYST PRODUCED BY USING THE SAME, RING-OPENING METATHESIS POLYMER OBTAINABLE WITH THE METATHESIS CATALYST, AND PROCESS FOR PRODUCING THE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-2045280-A1 | RING-OPENING METATHESIS POLYMERS, PRODUCTS OF HYDROGENATION THEREOF, PROCESS FOR PRODUCTION OF THE SAME AND USES THEREOF | Mitsui Chemicals, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-1950216-A1 | PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND, METATHESIS CATALYST PRODUCED BY THE PROCESS, METATHESIS POLYMER FORMED BY RING OPENING POLYMERIZATION WITH THE SAME, AND PROCESS FOR PRODUCING POLYMER WITH THE SAME | Mitsui Chemicals, Inc. (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124772-A1 | PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND, METATHESIS CATALYST PRODUCED BY USING THE SAME, RING-OPENING METATHESIS POLYMER OBTAINABLE WITH THE METATHESIS CATALYST, AND PROCESS FOR PRODUCING THE POLYMER | PORCN, ICMT, ME1 | TSHR 4344/4885ADH1B 2438/4885ADH1C 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.